Significant Movements: Argos Therapeutics, Inc. (NASDAQ:ARGS)

The independent data monitoring committee in the ADAPT study of the drug in patients with metastatic renal cell carcinoma (RCC) recommended that the trial be discontinued as there was little chance that Argos' drug would meet its targets. The company plans to leave the ADAPT trial open while the company conducts its ongoing data review and discussions with FDA.

ARGS has been the topic of several other reports. Number of analysts are covering this stock and now stock has got OUTPERFORM rating from 22 analysts of Thomson Reuters, 3 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating.

According to Yahoo Finance, the price target for the company which analysts are aiming is 13.

With a total market value of $0, Argos Therapeutics has with a 52 week low of $1.25 and a 52 week high of $13.97. Finally, Zacks Investment Research upgraded shares of Argos Therapeutics from a hold rating to a buy rating and set a $6.00 target price on the stock in a report on Monday, January 16th. (NASDAQ:ARGS) where 0 analyst have rated the stock as Strong Buy, 0 analysts said it's a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell.

In the last trading session, The Company traded 7.26 Million shares.

Argos Therapeutics Inc has a 50 day moving average of 4.94 and a 200 day moving average of 4.77. Post opening the session at $4.8, the shares hit an intraday low of $4.2 and an intraday high of $4.8 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of USA and worldwide trademark & copyright laws.

08/11/2016 - Argos Therapeutics Inc had its " rating reiterated by analysts at FBR Capital Markets.

Large investors have recently modified their holdings of the company.

04/19/2016 - Argos Therapeutics Inc had its " rating reiterated by analysts at Roth Capital. Bank of New York Mellon Corp boosted its stake in shares of Argos Therapeutics by 184.5% in the second quarter.

For the time being, the Durham, North Carolina-based Argos has chose to keep the trial open while it performs the necessary data review and looks forward to having discussions with the Food And Drug Administration (FDA) before taking a call on the drug program. Sanders Morris Harris Inc. boosted its stake in shares of Argos Therapeutics by 109.9% in the third quarter. Additionally, ARGS had a day price range of $1.25 to $1.6.

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate personalized immunotherapies.

  • Leroy Wright